January 26, 2017: Bragar Eagel & Squire, P.C., announce that the court has granted final approval of the settlement in In re Cornerstone Therapeutics Inc. Stockholder Litigation, Consolidated C.A. No. 8922-VCG, Court of Chancery of the State of Delaware.  Plaintiffs brought this action alleging that Defendants breached their fiduciary duties by approving the acquisition of Cornerstone Therapeutics Inc. (“Cornerstone”) by Chiesi Farmaceutici S.p.A. at an unfair price of 9.50 per share.  Pursuant to the settlement,, in return for releases and dismissal of the claims, Defendants will pay $17,881,555.20 for the benefit of the Class.  This amount represents a $2.40 per share, or a 25.2% premium above the merger price.  A copy of the settlement agreement and exhibits can be obtained through the Court’s website.

Attorney Advertising.  Prior results do not guarantee a similar outcome.

Report a Fraud or

Contact an Attorney



Fill out the form below to receive a free and confidential initial consultation.

No attorney/client relationship will be formed by sending an email through this site or receiving a response from Bragar Eagel & Squire, P.C. If you communicate with us through this website or otherwise in connection with a matter in which we do not already represent you, your communication may not be treated as privileged or confidential. Please avoid sending any sensitive or confidential messages by email.

*I accept

© 2017-2020 BRAGAR EAGEL & SQUIRE, P.C.